CR9433A - Remedio para xantoma - Google Patents

Remedio para xantoma

Info

Publication number
CR9433A
CR9433A CR9433A CR9433A CR9433A CR 9433 A CR9433 A CR 9433A CR 9433 A CR9433 A CR 9433A CR 9433 A CR9433 A CR 9433A CR 9433 A CR9433 A CR 9433A
Authority
CR
Costa Rica
Prior art keywords
remedy
xantoma
xanthoma
prodrug
salt
Prior art date
Application number
CR9433A
Other languages
English (en)
Inventor
Shiomi Masashi
Ito Takashi
Tozawa Ryuichi
Amano Yuichiro
Original Assignee
Takeda Pharmaceutical
Nat Univ Corp Univ Kobe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical, Nat Univ Corp Univ Kobe filed Critical Takeda Pharmaceutical
Publication of CR9433A publication Critical patent/CR9433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion se refiere a una medida preventiva/remedio para el xantoma el cual contiene un compuesto que tiene un efecto inhibitorio sobre la escualeno sintasa, su profarmaco o su sal.
CR9433A 2005-04-22 2007-10-11 Remedio para xantoma CR9433A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005124781 2005-04-22

Publications (1)

Publication Number Publication Date
CR9433A true CR9433A (es) 2008-02-22

Family

ID=37214809

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9433A CR9433A (es) 2005-04-22 2007-10-11 Remedio para xantoma

Country Status (14)

Country Link
US (1) US20090082333A1 (es)
EP (1) EP1889632A4 (es)
JP (1) JPWO2006115193A1 (es)
KR (1) KR20080015395A (es)
CN (1) CN101203243A (es)
AU (1) AU2006240710A1 (es)
BR (1) BRPI0610724A2 (es)
CA (1) CA2605365A1 (es)
CR (1) CR9433A (es)
IL (1) IL186528A0 (es)
MA (1) MA29401B1 (es)
NO (1) NO20075387L (es)
RU (1) RU2007143325A (es)
WO (1) WO2006115193A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3479796B2 (ja) * 1995-09-13 2003-12-15 武田薬品工業株式会社 ベンゾオキサゼピン化合物
JP2004089148A (ja) * 2002-09-04 2004-03-25 Oriental Yeast Co Ltd 心筋梗塞発症ウサギ
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds

Also Published As

Publication number Publication date
EP1889632A1 (en) 2008-02-20
CN101203243A (zh) 2008-06-18
IL186528A0 (en) 2008-01-20
JPWO2006115193A1 (ja) 2008-12-18
AU2006240710A1 (en) 2006-11-02
CA2605365A1 (en) 2006-11-02
EP1889632A4 (en) 2010-07-14
NO20075387L (no) 2008-01-21
KR20080015395A (ko) 2008-02-19
BRPI0610724A2 (pt) 2016-11-16
WO2006115193A1 (ja) 2006-11-02
MA29401B1 (fr) 2008-04-01
US20090082333A1 (en) 2009-03-26
RU2007143325A (ru) 2009-05-27

Similar Documents

Publication Publication Date Title
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
CL2012002252A1 (es) Conjunto antidesgaste que incluye un elemento antidesgaste que va a montarse en un implemento o aparato que va a protegerse, un elemento de base que va a acoplarse al implemento o aparato, un elemento de bloqueo para bloquear dicho elemento antidesgaste con respecto a dicho elemento de base; base para un conjunto antidesgaste; bloqueo ; elemento de bloqueo; conjunto antidesgaste.
CU24128B1 (es) Compuesto de benzoato conjugado a la hidrocodona (bz-hc)
CR20110581A (es) Preparación de solido
HN2008001723A (es) Nitrilos espirociclicos como inhibidores de proteasa
BRPI0811189A2 (pt) Ferramenta de nivelação composta.
UY31688A1 (es) Plaguicidas
SV2009002836A (es) Etiqueta para orejas de animales
ECSP11011307A (es) Comprimidos para terapia de combinacion
HN2009000113A (es) Derivados novedosos de aminopiridina que tiene accion inhibidora selectiva sobre aurora a
PA8782301A1 (es) Tratamiento de leucemia resistente al imatinte
GT200900153A (es) Agentes para combatir parasitos en animales
HN2005035436A (es) Caja de empaque
ECSP088374A (es) Formulacion de aerosol para inhalacion
CR9692A (es) Derivados de 2-oxo-imidazol sustituidos con dihidroxialquilo en n
BRPI0815716A2 (pt) Decapagem secundária econômica.
HN2005035438A (es) Caja de empaque
HN2005035435A (es) Caja de empaque
CR9433A (es) Remedio para xantoma
ES1059722Y (es) Cuerda para elementos de proteccion individual.
CL2007003838A1 (es) Composiciones farmaceuticas que contienen compuestos semisinteticos derivados de los alcaloides de la vinca, utiles para tratar el cancer.
HN2005035440A (es) Caja de empaque
MX2007012935A (es) Remedio para xantoma.
ES1059883Y (es) Rotulo para invidentes.
ES1061253Y (es) Funda protectora.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)